Aragen Life Sciences begins operations at high-potency platform in Hyderabad
Benchmarks Nifty22,622.70-99.25FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.71 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return19.29 % Invest NowEnter search…
Aragen Life Sciences has initiated operations at its new high-potency manufacturing platform in Hyderabad. The facility, measuring 15,000 square feet, can produce 500-600 kg of active pharmaceutical ingredients annually. It aims to streamline the transition of highly potent molecules from discovery to commercial supply. The company has invested over Rs 1,000 crore in capital expenditures over three years.
Listen to this article in summarized format
Loading...×New Delhi: Contract research, development and manufacturing organisation Aragen Life Sciences on Wednesday announced that it has started operations at its integrated high-potency development and manufacturing platform set up at its Nacharam campus in Hyderabad.The 15,000-square-foot facility operates a manufacturing line designed to produce 500-600 kg of active pharmaceutical ingredients (API) annually. It integrates discovery, process development, and cGMP manufacturing for highly potent molecules, including cytotoxic payloads used in oncology, to minimise handoffs across the development journey, according to a statement on Wednesday.
The platform, Aragen OneHP, is designed to handle compounds at occupational exposure limits of up to 10 ng/m³ and lays the groundwork for expansion into advanced modalities, such as antibody-drug conjugates and peptide-drug conjugates.
Also read: Centre may seek legal view on licensing of sterile drugs
Aniel Khubchandani, Chief Executive Officer, Small Molecules-CDMO, Aragen said, "With OneHP, we are bringing discovery, development and cGMP manufacturing for highly potent molecules onto a more integrated platform. This can reduce handoffs between providers, while keeping process knowledge and programme context connected as a molecule moves from early development towards commercial supply.
Live Events
The company stated that it invested over Rs 1,000 crore in capital expenditure over the three years leading to March 2026. Its contract development and manufacturing segment registered a 19 per cent compound annual growth rate during this timeframe, with installed small-molecule capacity reaching 364 KL across its Hyderabad and Visakhapatnam sites.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onAragen Life Sciencesactive pharmaceutical ingredients (API)oncology drug developmentcGMP manufacturingintegrated manufacturing platformcontract research organizationHyderabad pharmaceutical industry
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
...moreless(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onAragen Life Sciencesactive pharmaceutical ingredients (API)oncology drug developmentcGMP manufacturingintegrated manufacturing platformcontract research organizationHyderabad pharmaceutical industry
(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)
...morelessStories you might be interested in
Figures reflect the source report and its stated period. This article is for information and is not investment advice.
